Oramed Pharmaceuticals Inc. (ORMP)

NASDAQ: ORMP · USD

$4.13

-0.03 (-0.7%)· Recorded snapshot

Market cap	171.8M
Net income (ttm)	174.1M
EPS (ttm)	$4.15
Shares out	41.6M
P/E (trailing)	1.0x
Dividend	$0.25 (6.03%)
Volume	40,152
Beta	1.28

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): 174.1M
EPS (ttm): $4.15
P/E (trailing): 1.0x
Market cap: 171.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ホールド

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/E1

P25 15.4P50 25.8P75 43.5

ROE74.2

P25 -113.8P50 -46.5P75 -0.9

ROIC-5.2

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All ORMP indicators

Market & fundamental data

Available fields

207

Groups with data

Currency

USD

Showing 207 of 207 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001176309
Company name	Oramed Pharmaceuticals Inc.
Country	United States
Country code	US
CUSIP number	68403P203
Earnings date	2026-11-12
Earnings time	amc
Employees	4
Enterprise value	$100.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2002
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US68403P2039
Last 10-K release date	2026-03-26
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split date	2013-01-23
Last stock split type	Reverse
Market cap	$171.8M
Market cap category	Micro-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$4.13
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ORMP
U.S. state	New York
Website	https://oramed.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (3Y)	7.76x
Earnings yield	100.43%
EV/Earnings	0.57x
FCF / EV yield	-5.21%
FCF yield	-3.04%
Graham number	26.7794
Graham upside	548.41%
P/B ratio	0.54x
P/E ratio	1x
Price / tangible book value	0.54x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Effective tax rate	20.62%
Profit per employee	$43.5M
Profitable quarters	5
Profitable years	1
ROA	-3.42%
ROCE	-4.05%
ROE	74.24%
ROIC	-5.23%
ROIC (5Y)	-157%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	493.55%
EPS growth (QoQ)	102.2%
EPS growth quarters	5
EPS growth years	1
Net income growth (Q)	488.17%
Net income growth (QoQ)	104.01%
Net income growth quarters	5
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-9,000
Depreciation and amortization	$122,000
EBIT	$-14.5M
EBITDA	$-14.4M
EPS	$4.15
FCF per share	$-0.13
Financing cash flow	$-16.7M
Free cash flow	$-5.2M
Free cash flow minus SBC	$-11.3M
Income taxes	$45.4M
Investing cash flow	$21.5M
Net cash flow	$-552,000
Net income	$174.1M
Operating cash flow minus SBC	$-11.3M
Operating income	$-14.5M
Stock-based compensation	$6.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.39
Book value per share	$7.68
Debt / equity	0
Long-term assets	$316.2M
Long-term liabilities	$41.4M
Net cash (debt)	$71.7M
Net cash / market cap	41.76%
Net cash growth	-26.06%
Net debt / equity	-0.23
Piotroski F-Score	1
Property, plant and equipment	$1.1M
Shareholders' equity	$317.5M
Tangible book value	$317.5M
Tangible book value per share	$7.68
Total assets	$369.6M
Total cash	$50.6M
Total debt	$733,000
Total liabilities	$52.2M
WACC	11.22%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$53.4M
Current liabilities	$10.7M
Current ratio	4.98
Net working capital	$-7.7M
Quick ratio	4.85
Working capital	$42.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.31%
Dividend growth	0%
Dividend growth years	0
Dividend payment date	2026-01-26
Dividend payment years	1
Dividend per share	$0.25
Dividend yield	6.03%
Ex-dividend date	2026-01-16
Last dividend	$0.25
Payout ratio	6.03%
Shareholder yield	3.75%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-38.65%
10Y return CAGR	-4.1%
10Y total return	-34.19%
150-day SMA	$4.23
15Y price change	-4.28%
15Y return CAGR	0.18%
15Y total return	2.67%
1D price change	-0.72%
1M price change	-12.58%
1M total return	-12.58%
1W price change	-0.36%
1W total return	-0.36%
1Y price change	74.47%
1Y return CAGR	87.23%
1Y total return	87.15%
20-day SMA	$4.23
200-day SMA	$4.03
20Y price change	-55.25%
20Y return CAGR	-3.6%
20Y total return	-52%
3M price change	-0.6%
3M total return	-0.6%
3Y price change	123.51%
3Y return CAGR	33.83%
3Y total return	139.76%
50-day SMA	$4.59
50-day SMA vs 200-day SMA	50over200
52-week high	$5.47
52-week high date	2026-08-27
52-week low	$2.09
52-week low date	2025-11-07
5Y price change	-82%
5Y return CAGR	-28.03%
5Y total return	-80.69%
6M price change	0.61%
6M total return	0.61%
All-time high	$31.73
All-time high date	2014-01-13
All-time low	$0.15
All-time low date	2004-03-19
Average true range (ATR)	$0.15
Average volume	133.7K
Beta (1Y)	0.8
Beta (2Y)	0.45
Beta (5Y)	1.28
Change from 52-week high	-24.5%
Change from 52-week low	97.61%
Change from all-time high	-86.97%
Change from all-time low	2,741.92%
Change from open	0.73%
Day's gap	-1.44%
Dollar volume	$165,828
High price	$4.15
Low price	$4.10
Monthly RSI	54.95
Open price	$4.10
Position in 52-week range	60%
Premarket change	-1.2%
Premarket close	$4.16
Premarket price	$4.11
Previous close	$4.16
Price vs 150-day SMA	-2.18%
Price vs 20-day SMA	-2.25%
Price vs 200-day SMA	2.73%
Price vs 50-day SMA	-9.97%
Relative volume	0.3
RSI	39.08
Sharpe ratio	1.37
Sharpe ratio (3Y)	0.71
Sharpe ratio (5Y)	0.02
Sortino ratio	2.44
Sortino ratio (3Y)	1.3
Sortino ratio (5Y)	0.1
Volume	40.2K
Weekly RSI	48.93
YTD price change	45.09%
YTD total return	55.63%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	29.8M
Float percentage	71.71%
Shares change (QoQ)	1.27%
Shares change (YoY)	2.31%
Shares held by insiders	22.25%
Shares held by institutions	34.74%
Shares outstanding	41.6M
Short % of float	4.81%
Short % of shares	3.45%
Short ratio	7.5 days

Deeper analysis on ORMP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ORMP report

Is a complete ORMP research report available?

No complete published report is available for Oramed Pharmaceuticals Inc. (ORMP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Oramed Pharmaceuticals Inc. (ORMP)

Price

Financial snapshot

Fair-value bridge

Latest news · ORMP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ORMP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ORMP

Frequently asked questions